Cargando…

Integrative Radiogenomics Approach for Risk Assessment of Postoperative and Adjuvant Chemotherapy Benefits for Gastric Cancer Patients

Gastric cancer (GC) is a typical heterogeneous malignant tumor, whose insensitivity to chemotherapy is a common cause of tumor recurrence and metastasis. There is no doubt regarding the effectiveness of adjuvant chemotherapy (ACT) for GC, but the population for whom it is indicated and the selection...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Yin, Xu, Yilun, Li, Yanyan, Chen, Renpin, Cai, Weiyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602567/
https://www.ncbi.nlm.nih.gov/pubmed/34804945
http://dx.doi.org/10.3389/fonc.2021.755271
_version_ 1784601602996305920
author Jin, Yin
Xu, Yilun
Li, Yanyan
Chen, Renpin
Cai, Weiyang
author_facet Jin, Yin
Xu, Yilun
Li, Yanyan
Chen, Renpin
Cai, Weiyang
author_sort Jin, Yin
collection PubMed
description Gastric cancer (GC) is a typical heterogeneous malignant tumor, whose insensitivity to chemotherapy is a common cause of tumor recurrence and metastasis. There is no doubt regarding the effectiveness of adjuvant chemotherapy (ACT) for GC, but the population for whom it is indicated and the selection of specific options remain the focus of present research. The conventional pathological TNM prediction focuses on cancer cells to predict prognosis, while they do not provide sufficient prediction. Enhanced computed tomography (CT) scanning is a validated tool that assesses the involvement of careful identification of the tumor, lymph node involvement, and metastatic spread. Using the radiomics approach, we selected the least absolute shrinkage and selection operator (LASSO) Cox regression model to build a radiomics signature for predicting the overall survival (OS) and disease-free survival (DFS) of patients with complete postoperative gastric cancer and further identifying candidate benefits from ACT. The radiomics trait-associated genes captured clinically relevant molecular pathways and potential chemotherapeutic drug metabolism mechanisms. Our results of precise surrogates using radiogenomics can lead to additional benefit from adjuvant chemotherapy and then survival prediction in postoperative GC patients.
format Online
Article
Text
id pubmed-8602567
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86025672021-11-20 Integrative Radiogenomics Approach for Risk Assessment of Postoperative and Adjuvant Chemotherapy Benefits for Gastric Cancer Patients Jin, Yin Xu, Yilun Li, Yanyan Chen, Renpin Cai, Weiyang Front Oncol Oncology Gastric cancer (GC) is a typical heterogeneous malignant tumor, whose insensitivity to chemotherapy is a common cause of tumor recurrence and metastasis. There is no doubt regarding the effectiveness of adjuvant chemotherapy (ACT) for GC, but the population for whom it is indicated and the selection of specific options remain the focus of present research. The conventional pathological TNM prediction focuses on cancer cells to predict prognosis, while they do not provide sufficient prediction. Enhanced computed tomography (CT) scanning is a validated tool that assesses the involvement of careful identification of the tumor, lymph node involvement, and metastatic spread. Using the radiomics approach, we selected the least absolute shrinkage and selection operator (LASSO) Cox regression model to build a radiomics signature for predicting the overall survival (OS) and disease-free survival (DFS) of patients with complete postoperative gastric cancer and further identifying candidate benefits from ACT. The radiomics trait-associated genes captured clinically relevant molecular pathways and potential chemotherapeutic drug metabolism mechanisms. Our results of precise surrogates using radiogenomics can lead to additional benefit from adjuvant chemotherapy and then survival prediction in postoperative GC patients. Frontiers Media S.A. 2021-11-05 /pmc/articles/PMC8602567/ /pubmed/34804945 http://dx.doi.org/10.3389/fonc.2021.755271 Text en Copyright © 2021 Jin, Xu, Li, Chen and Cai https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Jin, Yin
Xu, Yilun
Li, Yanyan
Chen, Renpin
Cai, Weiyang
Integrative Radiogenomics Approach for Risk Assessment of Postoperative and Adjuvant Chemotherapy Benefits for Gastric Cancer Patients
title Integrative Radiogenomics Approach for Risk Assessment of Postoperative and Adjuvant Chemotherapy Benefits for Gastric Cancer Patients
title_full Integrative Radiogenomics Approach for Risk Assessment of Postoperative and Adjuvant Chemotherapy Benefits for Gastric Cancer Patients
title_fullStr Integrative Radiogenomics Approach for Risk Assessment of Postoperative and Adjuvant Chemotherapy Benefits for Gastric Cancer Patients
title_full_unstemmed Integrative Radiogenomics Approach for Risk Assessment of Postoperative and Adjuvant Chemotherapy Benefits for Gastric Cancer Patients
title_short Integrative Radiogenomics Approach for Risk Assessment of Postoperative and Adjuvant Chemotherapy Benefits for Gastric Cancer Patients
title_sort integrative radiogenomics approach for risk assessment of postoperative and adjuvant chemotherapy benefits for gastric cancer patients
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602567/
https://www.ncbi.nlm.nih.gov/pubmed/34804945
http://dx.doi.org/10.3389/fonc.2021.755271
work_keys_str_mv AT jinyin integrativeradiogenomicsapproachforriskassessmentofpostoperativeandadjuvantchemotherapybenefitsforgastriccancerpatients
AT xuyilun integrativeradiogenomicsapproachforriskassessmentofpostoperativeandadjuvantchemotherapybenefitsforgastriccancerpatients
AT liyanyan integrativeradiogenomicsapproachforriskassessmentofpostoperativeandadjuvantchemotherapybenefitsforgastriccancerpatients
AT chenrenpin integrativeradiogenomicsapproachforriskassessmentofpostoperativeandadjuvantchemotherapybenefitsforgastriccancerpatients
AT caiweiyang integrativeradiogenomicsapproachforriskassessmentofpostoperativeandadjuvantchemotherapybenefitsforgastriccancerpatients